Zacks Investment Research downgraded shares of AETERNA ZENTARS (AEZS) from OUTPERFORM to NEUTRAL on November 16, 2012, with a target price of $2.30.
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on AETERNA ZENTARS (AEZS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment